Switch to Vildagliptin, oral hypoglycemic agent therapy, from Liraglutide injection

Trial Profile

Switch to Vildagliptin, oral hypoglycemic agent therapy, from Liraglutide injection

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Sep 2012

At a glance

  • Drugs Vildagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms SWITCH-1
  • Most Recent Events

    • 18 Sep 2012 Planned End Date changed from 1 Mar 2013 to 1 May 2013 as reported by University Hospital Medical Information Network - Japan.
    • 10 May 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top